EP2152268A1 - Method of treating diabetes - Google Patents

Method of treating diabetes

Info

Publication number
EP2152268A1
EP2152268A1 EP07797962A EP07797962A EP2152268A1 EP 2152268 A1 EP2152268 A1 EP 2152268A1 EP 07797962 A EP07797962 A EP 07797962A EP 07797962 A EP07797962 A EP 07797962A EP 2152268 A1 EP2152268 A1 EP 2152268A1
Authority
EP
European Patent Office
Prior art keywords
ranolazine
diabetic
patient
cardiovascular disease
lower alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07797962A
Other languages
German (de)
English (en)
French (fr)
Inventor
Marcus Jerling
Andrew Wolff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of EP2152268A1 publication Critical patent/EP2152268A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • Methods are provided for treating diabetes, lowering plasma level of HbAIc, in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease comprising administering ranolazine to these patients.
  • Diabetes mellitus is a disease characterized by hyperglycemia; altered metabolism of lipids, carbohydrates and proteins; and an increased risk of complications from vascular disease. Diabetes is an increasing public health problem, as it is associated with both increasing age and obesity.
  • Type I also known as insulin dependent diabetes (IDDM)
  • Type II also known as insulin independent or non- insulin dependent diabetes (NIDDM). Both types of diabetes mellitus are due to insufficient amounts of circulating insulin and a decrease in the response of peripheral tissue to insulin.
  • Type I diabetes results from the body's failure to produce insulin, the hormone that "unlocks" the cells of the body, allowing glucose to enter and fuel them.
  • the complications of Type I diabetes include heart disease and stroke; retinopathy (eye disease); kidney disease (nephropathy); neuropathy (nerve damage); as well as maintenance of good skin, foot and oral health.
  • Type II diabetes results from the body's inability to either produce enough insulin or the cells inability to use the insulin that is naturally produced by the body.
  • the condition where the body is not able to optimally use insulin is called insulin resistance.
  • Type II diabetes is often accompanied by high blood pressure and this may contribute to heart disease.
  • stress, infection, and medications can also lead to severely elevated blood sugar levels.
  • severe blood sugar elevation in patients with type II diabetes can lead to an increase in blood osmolality (hyperosmolar state). This condition can lead to coma.
  • Insulin lowers the concentration of glucose in the blood by stimulating the uptake and metabolism of glucose by muscle and adipose tissue. Insulin stimulates the storage of glucose in the liver as glycogen, and in adipose tissue as triglycerides. Insulin also promotes the utilization of glucose in muscle for energy. Thus, insufficient insulin levels in the blood, or decreased sensitivity to insulin, gives rise to excessively high levels of glucose and triglycerides in the blood.
  • the early symptoms of untreated diabetes mellitus are related to elevated blood sugar levels, and loss of glucose in the urine.
  • High amounts of glucose in the urine can cause increased urine output and lead to dehydration.
  • Dehydration causes increased thirst and water consumption.
  • the inability to utilize glucose energy eventually leads to weight loss despite an increase in appetite.
  • Some untreated diabetes patients also complain of fatigue, nausea, and vomiting. Patients with diabetes are prone to developing infections of the bladder, skin, and vaginal areas. Fluctuations in blood glucose levels can lead to blurred vision. Extremely elevated glucose levels can lead to lethargy and coma (diabetic coma).
  • IGT impaired glucose tolerance
  • the toxic effects of excess plasma levels of glucose include the glycosylation of cells and tissues. Glycosylated products accumulate in tissues and may eventually form cross-linked proteins, which cross-linked proteins are termed advanced glycosylation end products. It is possible that non-enzymatic glycosylation is directly responsible for expansion of the vascular matrix and vascular complications of diabetes. For example, glycosylation of collagen results in excessive cross-linking, resulting in atherosclerotic vessels. Also, the uptake of glycosylated proteins by macrophages stimulates the secretion of pro-inflammatory cytokines by these cells. The cytokines activate or induce degradative and proliferative cascades in mesenchymal and endothelial cells respectively.
  • the glycosylation of hemoglobin provides a convenient method to determine an integrated index of the glycemic state.
  • the level of glycosylated proteins reflects the level of glucose over a period of time and is the basis of an assay referred to as the hemoglobulin Al (HbAIc) assay
  • HbAIc reflects a weighted average of blood glucose levels during the previous
  • AIc also known as HbAIc, glycohemoglobin, or glycated hemoglobin
  • HbAIc glycohemoglobin
  • glycated hemoglobin indicates how well diabetes has been controlled over the last few months. The closer AIc is to 6%, the better the control of diabetes. For every 30 mg/dl increase in AIc blood glucose, there is a 1% increase in AIc, and the risk of complications increases.
  • sorbitol formation Intracellular glucose is reduced to its corresponding sugar alcohol, sorbitol, by the enzyme aldose reductase; the rate of production of sorbitol is determined by the ambient glucose concentration.
  • tissues such as lens, retina, arterial wall and
  • Schwann cells of peripheral nerves have high concentrations of sorbitol.
  • Hyperglycemia also impairs the function of neural tissues because glucose competes with myoinositol resulting in reduction of cellular concentrations and, consequently, altered nerve function and neuropathy.
  • Increased triglyceride levels are also a consequence of insulin deficiency.
  • High triglyceride levels are also associated with vascular disease.
  • Medications that increase the insulin output by the pancreas include sulfonylureas (including chlorpropamide [Orinase®], tolbutamide [Tolinase®], glyburide [Micronase®], glipizide [Glucotrol®], and glimepiride [Amaryl®]) and meglitinides (including reparglinide [Prandin®] and nateglinide [Starlix®]).
  • Medications that decrease the amount of glucose produced by the liver include biguanides (including metformin
  • Medications that increase the sensitivity of cells to insulin include thazolidinediones (including troglitazone [Resulin®], pioglitazone [Actos®] and rosiglitazone [Avandia®]).
  • Medications that decrease the absorption of carbohydrates from the intestine include alpha glucosidase inhibitors (including acarbose [Precose®] and miglitol [Glyset®]). Actos® and Avandia® can change the cholesterol patterns in diabetics. HDL (or good cholesterol) increases on these medications.
  • Precose® works on the intestine; its effects are additive to diabetic medications that work at other sites, such as sulfonylureas.
  • ACE inhibitors can be used to control high blood pressure, treat heart failure, and prevent kidney damage in people with hypertension or diabetes.
  • ACE inhibitors or combination products of an ACE inhibitor and a diuretic, such as hydrochlorothazide, are marketed. However, none of these treatments is ideal.
  • Blood pressure control can reduce cardiovascular disease (for example, myocardial infarction and stroke) by approximately 33% to 50% and can reduce microvascular disease (eye, kidney, and nerve disease) by approximately 33%.
  • Total cholesterol should be less than 200 mg/dl.
  • Target levels for high density lipoprotein (HDL or "good” cholesterol) are above 45 mg/dl for men and above 55 mg/dl for women, while low density lipoprotein (LDL or "bad” cholesterol) should be kept below 100 mg/dl.
  • Target triglyceride levels for women and men are less than 150 mg/dl.
  • DPP Diabetes Prevention Program
  • ranolazine ( ⁇ )-N-(2,6-dimethylphenyl)-4-[2- hydroxy-3-(2-methoxyphenoxy)-propyl]-l-piperazineacetamide, and its pharmaceutically acceptable salts, and their use in the treatment of cardiovascular diseases, including arrhythmias, variant and exercise-induced angina, and myocardial infarction.
  • ranolazine is represented by the formula:
  • This patent also discloses intravenous (IV) formulations of dihydrochloride ranolazine further comprising propylene glycol, polyethylene glycol 400, Tween 80 and 0.9% saline.
  • IV intravenous
  • U.S. Patent No. 5,506,229 which is incorporated herein by reference in its entirety, discloses the use of ranolazine and its pharmaceutically acceptable salts and esters for the treatment of tissues experiencing a physical or chemical insult, including cardioplegia, hypoxic or reperfusion injury to cardiac or skeletal muscle or brain tissue, and for use in transplants. Oral and parenteral formulations are disclosed, including controlled release formulations.
  • 5,506,229 describes a controlled release formulation in capsule form comprising microspheres of ranolazine and microcrystalline cellulose coated with release controlling polymers.
  • This patent also discloses IV ranolazine formulations which at the low end comprise 5 mg ranolazine per milliliter of an IV solution containing about 5% by weight dextrose. And at the high end, there is disclosed an IV solution containing 200 mg ranolazine per milliliter of an IV solution containing about 4% by weight dextrose.
  • ranolazine and its pharmaceutically acceptable salts and esters is oral.
  • a typical oral dosage form is a compressed tablet, a hard gelatin capsule filled with a powder mix or granulate, or a soft gelatin capsule (softgel) filled with a solution or suspension.
  • U.S. Patent No. 5,472,707 discloses a high-dose oral formulation employing supercooled liquid ranolazine as a fill solution for a hard gelatin capsule or softgel.
  • U.S. Patent No. 6,503,911 discloses sustained release formulations that overcome the problem of affording a satisfactory plasma level of ranolazine while the formulation travels through both an acidic environment in the stomach and a more basic environment through the intestine, and has proven to be very effective in providing the plasma levels that are necessary for the treatment of angina and other cardiovascular diseases.
  • ranolazine sustained release formulations of the invention include a pH dependent binder; a pH independent binder; and one or more pharmaceutically acceptable excipients.
  • Suitable pH dependent binders include, but are not limited to, a methacrylic acid copolymer, for example Eudragit ® (Eudragit® LlOO- 55, pseudolatex of Eudragit® L100-55, and the like) partially neutralized with a strong base, for example, sodium hydroxide, potassium hydroxide, or ammonium hydroxide, in a quantity sufficient to neutralize the methacrylic acid copolymer to an extent of about 1-20%, for example about 3-6%.
  • Suitable pH independent binders include, but are not limited to, hydroxypropylmethylcellulose (HPMC), for example Methocel® ElOM Premium CR grade HPMC or Methocel® E4M Premium HPMC.
  • Suitable pharmaceutically acceptable excipients include magnesium stearate and microcrystalline cellulose (Avicel® pHlOl).
  • ranolazine provides a method of treating diabetes prediabetes, or the non-diabetes condition by reducing the levels of potentially toxic metabolites in blood and/or complications associated with diabetes. Ranolazine also can reduce the number of medications necessary for a patient with both cardiovascular problems and diabetes or pre-diabetes.
  • the invention relates to a method of lowering the plasma level of HbAIc in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease, comprising administration of a therapeutically effective amount of a compound of Formula I:
  • R 1 , R 2 , R 3 , R 4 and R 5 are each independently hydrogen, lower alkyl, lower alkoxy, cyano, trifluoromethyl, halo, lower alkylthio, lower alkyl sulfinyl, lower alkyl sulfonyl, or N-optionally substituted alkylamido, provided that when R 1 is methyl, R 4 is not methyl; or R 2 and R 3 together form -OCH 2 O-;
  • R 11 and R 12 are each independently hydrogen or lower alkyl
  • W is oxygen or sulfur; or a pharmaceutically acceptable salt or ester thereof, or an isomer thereof.
  • a preferred compound of this invention is ranolazine, which is named N-(2,6- dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-l-piperazineacetamide, as a racemic mixture, or an isomer thereof, or a pharmaceutically acceptable salt thereof.
  • a second aspect of this invention is a method of lowering the plasma level of
  • HbAIc in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease, wherein the cardiovascular disease is angina.
  • a third aspect of this invention is a method of lowering the plasma level of
  • HbAIc in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease, wherein the cardiovascular disease is chronic angina.
  • a fourth aspect of this invention is a method of lowering the plasma level of
  • HbAIc in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease comprising administering a therapeutically effective amount of ranolazine.
  • a fifth aspect of this invention is a method of lowering the plasma level of
  • HbAIc in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease, comprising administration of a therapeutically effective amount of a compound of Formula I:
  • R 1 , R 2 , R 3 , R 4 and R 5 are each independently hydrogen, lower alkyl, lower alkoxy, cyano, trifluoromethyl, halo, lower alkylthio, lower alkyl sulfinyl, lower alkyl sulfonyl, or N-optionally substituted alkylamido, provided that when R 1 is methyl, R 4 is not methyl; or R 2 and R 3 together form -OCH 2 0-;
  • R 6 , R 7 , R 8 , R 9 and R 10 are each independently hydrogen, lower acyl, aminocarbonylmethyl, cyano, lower alkyl, lower alkoxy, trifluoromethyl, halo, lower alkylthio, lower alkyl sulfinyl, lower alkyl sulfonyl, or di-lower alkyl amino; or
  • R 7 and R 8 together form -0-CH 2 O-;
  • R 11 and R 12 are each independently hydrogen or lower alkyl
  • W is oxygen or sulfur; or a pharmaceutically acceptable salt or ester thereof, or an isomer thereof; to a mammal in need thereof, wherein the compound of Formula I is administered as an immediate release formulation.
  • a sixth aspect of this invention is a method of lowering the plasma level of
  • HbAIc in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease, comprising administration of a therapeutically effective amount of a compound of Formula I:
  • R 1 , R 2 , R 3 , R 4 and R 5 are each independently hydrogen, lower alkyl, lower alkoxy, cyano, trifluoromethyl, halo, lower alkylthio, lower alkyl sulfinyl, lower alkyl sulfonyl, or N-optionally substituted alkylamido, provided that when R 1 is methyl, R 4 is not methyl; or R 2 and R 3 together form -OCH 2 O-;
  • R 11 and R 12 are each independently hydrogen or lower alkyl
  • W is oxygen or sulfur; or a pharmaceutically acceptable salt or ester thereof, or an isomer thereof; to a mammal in need thereof, wherein the compound of Formula I is administered as a sustained release formulation.
  • a seventh aspect of this invention is a method of lowering the plasma level of
  • HbAIc in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease, comprising administration of a therapeutically effective amount of a compound of Formula I to a mammal in need thereof, wherein the compound of
  • Formula I is administered in a formulation that has both immediate release and sustained release aspects.
  • An eighth aspect of this invention is a method of lowering the plasma level of
  • HbAIc in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease comprising administration of a therapeutically effective amount of a sustained release formulation comprising a compound of Formula I to a mammal in need thereof, wherein the sustained release formulation provides a plasma level of ranolazine between 550 and 7500 ng base/ml over a 24 hour period.
  • a ninth aspect of the invention is a method of lowering the plasma level of
  • HbAIc in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease comprising administering a compound of Formula I wherein the dosage is from about 250 mg bid to about 2000 mg bid to a mammal.
  • a tenth aspect of this invention is a method of lowering the plasma level of
  • HbAIc in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease comprising administering from about 250 mg bid to about 2000 mg bid of ranolazine.
  • An eleventh aspect of this invention is a method of reducing negative consequences of diabetes comprising administration of ranolazine.
  • a twelfth aspect of this invention is a method of delaying or slowing the development of diabetes comprising administration of ranolazine.
  • a thirteenth aspect of this invention is a method of delaying the initiation of insulin treatment comprising administration of ranolazine.
  • a fourteenth aspect of this invention is a method of reducing HbAIc levels in a patient without leading to hypoglycemia comprising administration of ranolazine.
  • a fifteenth aspect of this invention is a method of delaying or slowing the development of worsening hyperglycemia in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease, comprising administration of ranolazine.
  • a sixteenth aspect of this invention is a method of reducing or slowing the development of hyperglycemia in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease, comprising administration of ranolazine.
  • FIG. 1 CARISA Primary Endpoint: Exercise Duration at Trough. This figure shows changes from baseline (in sec) for diabetics and non-diabetics on placebo, 750 mg ranolazine bid, or 1000 mg ranolazine bid.
  • CARISA Exercise Time to Onset of Angina. This figure shows changes from baseline (in sec) in trough and peak for diabetics and non-diabetics on placebo, 750 mg ranolazine bid, or 1000 mg ranolazine bid.
  • FIG. 6 CARISA: Change from Baseline in HbAIc (all diabetic patients). This figure shows percentage of HbAIc for diabetics on placebo, 750 mg ranolazine bid, or 1000 mg ranolazine bid at baseline and at last study value.
  • FIG. 7 CARISA: Change from Baseline in HbAIc (Dependent vs Non- insulin Dependent Diabetic Patients. This figure shows percentage of HbAIc for both insulin dependent and non-insulin dependent diabetics on placebo, 750 mg ranolazine bid, or 1000 mg ranolazine bid at baseline and at last study value.
  • Figure 8 Change in HbAIc (%).
  • Figure 8A shows the percentage change in HbAIa in patients diagnosed with diabetes mellitus before or at the start of randomization for this trial versus the months (16) of follow-up.
  • Figure 8A shows
  • Figure 8B shows the percentage change in HbAIc in patients that were either pre-diabetic or non-diabetic at the start of randomization for this trial (had not been diagnosed as diabetic before the start of this trial) versus the months (16) of follow-up.
  • Figure 8B shows
  • the invention provides a method of lowering the plasma level of HbAIc in a diabetic, pre-diabetic, or non-diabetic patient suffering from at least one cardiovascular disease, comprising administration of a compound of Formula I.
  • Diabetes as defined herein, is a disease state characterized by hyperglycemia; altered metabolism of lipids, carbohydrates, and proteins; and an increased risk of complications from vascular disease.
  • Pre-diabetes includes people with glucose levels between normal and diabetic have impaired glucose tolerance (IGT). This condition is also called pre-diabetes or insulin resistance syndrome. People with IGT do not have diabetes, but rather have blood glucose levels that are higher than normal but not yet high enough to be diagnosed as diabetes. Their bodies make more and more insulin, but because the tissues don't respond to it, their bodies can't use sugar properly.
  • IGT impaired glucose tolerance
  • Glycemic control is the regulation of blood glucose levels Hemoglobin undergoes glycosylation on its amino terminal valine residue to form the glucosyl valine adduct of hemoglobin (HbAIc)
  • HbAIc glucosyl valine adduct of hemoglobin
  • the toxic effects of hyperglycemia may be the result of accumulation of such nonenzymatically glycosylated products.
  • the covalent reaction of glucose with hemoglobin also provides a convenient method to determine an integrated index of the glycemic state. For example, the half-life of the modified hemoglobin is equal to that of the erythrocyte (about 120 days).
  • HbAIc Since the amount of glycosylated protein is proportional to the glucose concentration and the time of exposure of the protein to glucose, the concentration of HbAIc in the circulation reflects the glycemic state over an extended period (4 to 12 weeks) prior to sampling. Thus, a rise in HbAIc from 5% to 10% suggests a prolonged doubling of the mean blood glucose concentration [0071] With respect to the compound of Formula I, the following words and phrases are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.
  • Aminocarbonylmethyl refers to a group having the following structure:
  • A represents the point of attachment
  • Halo or “halogen” refers to fluoro, chloro, bromo or iodo.
  • “Lower acyl” refers to a group having the following structure:
  • R. is lower alkyl as is defined herein, and A represents the point of attachment, and includes such groups as acetyl, propanoyl, n-butanoyl and the like.
  • “Lower alkyl” refers to an unbranched saturated hydrocarbon chain of 1-4 carbons, such as methyl, ethyl, n-propyl, and n-butyl.
  • “Lower alkoxy” refers to a group —OR wherein R is lower alkyl as herein defined.
  • Lower alkylthio refers to a group -SR wherein R is lower alkyl as herein defined.
  • “Lower alkyl sulfinyl” refers to a group of the formula:
  • R ⁇ f ⁇ wherein R is lower alkyl as herein defined, and A represents the point of attachment.
  • “Lower alkyl sulfonyl” refers to a group of the formula:
  • N-Optionally substituted alkylamido refers to a group having the following structure:
  • R is independently hydrogen or lower alkyl and R' is lower alkyl as defined herein, and A represents the point of attachment.
  • compound of Formula I is intended to encompass the compounds of the invention as disclosed, and the pharmaceutically acceptable salts, pharmaceutically acceptable esters, and prodrugs of such compounds.
  • isomers refers to compounds having the same atomic mass and atomic number but differing in one or more physical or chemical properties. All isomers of the compounds of Formula I, including the R- and S- enantiomers are within the scope of the invention.
  • the compounds of this invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • pharmaceutically acceptable salt refers to salts that retain the biological effectiveness and properties of the compounds of Formula I, and which are not biologically or otherwise undesirable.
  • Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases, include by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, di(substituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl) amines, substituted cycloalkyl amines, disubstituted cycloalkyl amine, trisubstituted cycloalkyl amines, cycloalkenyl amines, di(cycloalkeny
  • Suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.
  • Salts derived from inorganic acids include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • therapeutically effective amount refers to that amount of a compound of Formula I that is sufficient to effect treatment, as defined below, when administered to a mammal in need of such treatment.
  • the therapeutically effective amount will vary depending upon the subject and disease condition being treated, the weight and age of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
  • treatment means any treatment of a disease in a mammal, including:
  • the "patient” is a mammal, preferably a human.
  • Physiologically acceptable pH refers to the pH of an intravenous solution which is compatible for delivery into a human patient.
  • physiologically acceptable pH's range from about 4 to about 8.5 and preferably from about 4 to 7.
  • the use of intravenous solutions having a pH of about 4 to 6 are deemed physiologically acceptable as the large volume of blood in the body effectively buffers these intravenous solutions.
  • Chronic diseases or "cardiovascular diseases” refer to diseases of the cardiovasculature arising from any one or more than one of, for example, heart failure, including congestive heart failure, acute heart failure, ischemia, recurrent ischemia, myocardial infarction, arrhythmias, angina (including exercise-induced angina, variant angina, stable angina, unstable angina), acute coronary syndrome, diabetes, and intermittent claudication.
  • heart failure including congestive heart failure, acute heart failure, ischemia, recurrent ischemia, myocardial infarction, arrhythmias, angina (including exercise-induced angina, variant angina, stable angina, unstable angina), acute coronary syndrome, diabetes, and intermittent claudication.
  • angina including exercise-induced angina, variant angina, stable angina, unstable angina
  • acute coronary syndrome diabetes
  • intermittent claudication The treatment of such disease states is disclosed in various U.S. patents and patent applications, including U.S. Patent Nos. 6,503,911
  • An acute coronary disease event refers to any condition relating to one or more coronary diseases which has/have manifested itself/themselves or has deteriorated to the point where the patient seeks medical intervention typically but not necessarily in an emergency situation.
  • Acute coronary syndrome refers to a range of acute myocardial ischemic states. It encompasses unstable angina and non-ST-segment elevation myocardial infarction (U A/N STEMI), and ST segment elevation myocardial infarction (STEMI). STEMI refers to a complete occlusion by thrombus.
  • ACS refers to those patients with a non-ST elevation acute coronary syndrome (NSTEACS).
  • NSTEACS refers to a partial occlusion by the thrombus.
  • NSTEACS is further defined as chest discomfort or anginal equivalent occurring at rest, lasting >10 minutes, and consistent with myocardial ischemia, and the presence of ischemic symptoms (>5 minutes) at rest within 48 hours of admittance which may include index episode, and having at least one of the following indicators of moderate - high risk:
  • a Risk Score of > 3 wherein one point is assigned for each of the following variables and a total score calculated as the arithmetic sum: o Age > 65 years; o Known CAD (prior MI, CABG, PCI or angiographic stenosis >50%); o Three or more cardiac risk factors (DM, elevated cholesterol, hypertension, family history); o More than one episode of ischemic discomfort at rest in o the prior 24 hours; o Chronic aspirin use in the 7 days preceding onset of symptoms; o ST segment depression > 0.05 mV; and o Elevated cardiac troponin or CK-MB.
  • risk indicators are also referred to as TIMI (thrombolysis in myocardial ischemia) risk factors and are further discussed in Chase, et al., Annals of Emergency Medicine, 48(3):252-259 (2006); Sadanandan, et al., J Am Coll Cardiol, 44(4):799-803 (2004); and Conway, et al., Heart, 92: 1333-1334 (2006), each of which is incorporated by reference in its entirety herein.
  • TIMI thrombolysis in myocardial ischemia
  • Unstable angina or "UA” refers to a clinical syndrome between stable angina and acute myocardial infarction. This definition encompasses many patients presenting with varying histories and reflects the complex pathophysiological mechanisms operating at different times and with different outcomes. Three main presentations have been described - angina at rest, new onset angina, and increasing angina.
  • ECG refers to an electrocardiogram
  • Cardiovascular intervention or “coronary intervention” refers to any invasive procedure to treat a coronary disease including, but not limited to, “percutaneous coronary intervention” or PCI. It is contemplated that PCI encompasses a number of procedures used to treat patients with diseases of the heart. Examples of PCI include, but are not limited to, PTCA (percutaneous transluminal coronary angioplasty), implantation of stents, pacemakers, and other coronary devices, CABG (coronary artery bypass graft surgery) and the like.
  • PTCA percutaneous transluminal coronary angioplasty
  • CABG coronary artery bypass graft surgery
  • Emergency refers to an acute situation in which the patient is initially seen by medical personnel.
  • Emergency situations can include, but are not limited to, medical facilities such as hospitals or clinics, emergency rooms at medical facilities such as hospitals or clinics, and emergency situations which involve police and/or medical personnel such as firemen, ambulance attendants, or other medically trained persons.
  • Stabilized or “stable” refers to a condition in which a patient is not considered to be in immediate risk of morbidity.
  • IR immediate release
  • sustained release refers to formulations or dosage units used herein that are slowly and continuously dissolved and absorbed in the stomach and gastrointestinal tract over a period of about six hours or more.
  • Preferred sustained release formulations are those exhibiting plasma concentrations of ranolazine suitable for no more than twice daily administration with two or less tablets per dosing as described below.
  • IV infusion or “intravenous administration” refers to solutions or dosage units used herein that are provided to the patient by intravenous route. Such IV infusions can be provided to the patient until for up to about 96 hours in order to stabilize the patient's cardiovascular condition. The method and timing for delivery of an IV infusion is within the skill of the attending medically trained person.
  • Renal insufficiency refers to when a patient's kidneys no longer have enough kidney function to maintain a normal state of health. Renal insufficiency includes both acute and chronic renal failure, including end-stage renal disease (ESRD). Methods of this Invention
  • this invention provides for a method for treating a diabetic, pre-diabetic, or non-diabetic patient suffering from an acute cardiovascular disease event.
  • the diabetic, pre- diabetic, or non-diabetic patient suffering from acute cardiovascular disease event exhibits one or more conditions associated with non-ST elevation acute coronary syndrome.
  • Patients presenting themselves with an acute coronary disease event include, but are not limited to, those who are being treated for one or more of the following: angina including stable angina, unstable angina (UA), exercised-induced angina, variant angina, arrhythmias, intermittent claudication, myocardial infarction including non- STE myocardial infarction (NSTEMI), heart failure including congestive (or chronic) heart failure, acute heart failure, or recurrent ischemia.
  • angina including stable angina, unstable angina (UA), exercised-induced angina, variant angina, arrhythmias, intermittent claudication, myocardial infarction including non- STE myocardial infarction (NSTEMI), heart failure including congestive (or chronic) heart failure, acute heart failure, or recurrent ischemia.
  • UA stable angina
  • exercised-induced angina including variant angina, arrhythmias, intermittent claudication
  • myocardial infarction including non- STE myocardial in
  • the methods of this aspect of the invention are preferably achieved by administering to the presenting patient an IV solution comprising a selected concentration of ranolazine.
  • an IV solution comprising a selected concentration of ranolazine.
  • the art provided IV solutions comprising ranolazine which comprised low concentrations of ranolazine (see, e.g., Kluge et al., U.S. Patent No. 4,567,264 where Example 11 of that patent describes using 1.4 mg of ranolazine per mL in an IV solution comprising significant amounts of both propylene glycol (20 g/100 mL) and polyethylene glycol (20 g/100 mL)).
  • Propylene glycol is a viscous liquid as is polyethylene glycol (see, e.g., the Merck Index, 12 th Ed., 1996).
  • the increased viscosity resulting from the use of such IV solutions makes the rapid delivery of ranolazine to the patient suffering from an acute cardiovascular disease event more cumbersome and requires that a significant amount of propylene glycol and polyethylene glycol be co-administered.
  • ranolazine which comprised either high or very high concentrations of ranolazine (either 5 mg/ mL or 200 mg/mL) relative to that employed in the IV solutions used herein. See, e.g., Dow, et al., U.S. Patent No. 5,506,229.
  • concentrations of ranolazine can result in higher ranolazine plasma levels. Accordingly, the use of such concentrations is contraindicated for treating patients presenting with an acute cardiovascular disease event as the attending physician has little if any time to assess the renal function of that patient prior to initiating treatment.
  • the IV solution has a selected amount of ranolazine comprising from about 1.5 to 3 mg per milliliter of solution, preferably about 1.8 to 2.2 mg per milliliter and, even more preferably, about 2 mg per milliliter.
  • the IV solution does not contain any propylene glycol or any polyethylene glycol.
  • the compositions of this invention comprise ranolazine, sterile water and dextrose monohydrate or sodium chloride. As such, the compositions of this invention are less viscous than those described by Kluge et al. allowing for more efficient rapid titration of the patient with the IV solution.
  • the rv solution of this invention is different from the injectable formulations since injectable formulations typically have excipients that may not be needed and may be contraindicated for IV formulations of this invention.
  • an injectable formulation can have an anti-spasmodic agent such as gluconic acid.
  • the IV solutions of this invention do not contain such anti-spasmodic agents and especially gluconic acid.
  • the rv solution of this invention is used to stabilize a diabetic, pre-diabetic, or non-diabetic patient suffering from an acute cardiovascular disease event.
  • the presenting patient is immediately administered this IV solution of ranolazine for a period until the patient is stabilized.
  • Such stabilization typically occurs within from about 12 to about 96 hours.
  • the patient suffering from an acute cardiovascular disease event is treated by:
  • IV solution comprises a selected concentration of ranolazine of from about 1.5 to about 3 mg per milliliter, preferably about 1.8 to about 2.2 mg per milliliter and, even more preferably, about 2 mg per milliliter;
  • titrating the IV administration of the IV ranolazine solution to the patient comprising: i) a sufficient amount of the IV solution to provide for about 200 mg of ranolazine delivered to the patient over about a 1 hour period; ii) followed by either: a sufficient amount of the IV solution to provide for about 80 mg of ranolazine per hour; or if said patient is suffering from renal insufficiency, a sufficient amount of the IV solution to provide for about 40 mg of ranolazine per hour; and
  • the infusion of the intravenous formulation of ranolazine is initiated such that a target peak ranolazine plasma concentration of about 2500 ng base/mL (wherein ng base/mL refers to ng of the free base of ranolazine/mL) is achieved.
  • ranolazine infusion for a patient experiencing adverse events deemed to be treatment related, is within the knowledge of the skilled in the art and, based on the concentration of ranolazine in the IV solution, easy to achieve.
  • Adverse events in addition to those described above include, but are not limited to, profound and persistent QTc prolongation, not attributed to other reversible factors such as hypokalemia; dizziness; nausea/vomiting; diplopia; parasthesia; confusion; and orthostatic hypotension.
  • the dose of intravenous solution of ranolazine may be adjusted to a lower dose such as, but not limited to, about 60 mg/hr, about 40 mg/hr, or about 30 mg/hr.
  • the intravenous delivery of ranolazine may be temporarily discontinued for 1-3 hrs and then restarted at the same or lower dose for patients experiencing adverse events deemed to be treatment related.
  • the diabetic, pre-diabetic, or non- diabetic patient is then administered an oral sustained release formulation of ranolazine.
  • this invention is particularly useful for treating a high risk coronary disease patient with a subsequent acute coronary disease event by treating a patient with ranolazine.
  • a high risk coronary patient is one who previously had at least one acute coronary disease event.
  • a high risk patient has a TIMI risk score of 3 or higher.
  • the oral dose of ranolazine is administered about 1 hour prior to the termination of the intravenous infusion of ranolazine.
  • the oral dose administered is 1000 mg once or twice daily (2 x 500 mg).
  • the oral dose administered is 750 mg once or twice daily (2 x 375 mg).
  • the oral dose administered is 500 mg (1 x 500 mg). In still another aspect of this embodiment, at the time of transition from intravenous to oral dose, for the intravenous dose of ranolazine of about 40 mg/hr, the oral dose administered is 500 mg (1 x 500 mg). In still another aspect of this embodiment, at the time of transition from intravenous to oral dose, for the intravenous dose of ranolazine of about 30 mg/hr, the oral dose administered is 375 mg (1 x 375 mg).
  • the oral dose of ranolazine can be adjusted for patients with newly developed severe renal insufficiency.
  • Other adverse events include, but are not limited to, profound and persistent QTc prolongation, not attributed to other reversible factors such as hypokalemia; dizziness; nausea/vomiting; diplopia; parasthesia; confusion; and orthostatic hypotension.
  • the oral dose of ranolazine may be adjusted downward to 500 mg once or twice daily, if not already at this dose or lower.
  • the oral dose of ranolazine may be adjusted to the next lower dose such as, but not limited to, 750 mg once or twice daily, 500 mg once or twice daily, or 375 mg once or twice daily.
  • a starting oral dose of 375 mg once or twice daily may be administered to a patient treated with moderate CYP3A inhibitors, such as, diltiazem >180 mg/day, fluconazole and the like, and P-gp inhibitors such as, verapamil, cyclosporine and the like.
  • the 1000 mg oral dose of ranolazine is administered such that a mean peak ranolazine plasma concentration of about 2500 ng base/mL + 1000 ng base/mL is achieved.
  • the invention relates to a method for reducing ischemia associated with cardiovascular intervention in a patient comprising intravenously administering an intravenous formulation of ranolazine at least about 4 hours and preferably about 6 hours prior to intervention.
  • the invention further comprises continuing to administer the ranolazine intravenously for at least about 4 hours and preferably about 6 hours after the intervention.
  • a patient receives intravenous ranolazine for at least about 4 hours or at least about 6 hours prior to the intervention and then receives intravenous ranolazine for at least about 4 hours or at least about 6 hours after intervention.
  • the ranolazine intravenously administered is an intravenous formulation as described herein.
  • the formulations of the invention can be used for treating various diseases, such as, cardiovascular diseases e.g., arteriosclerosis, hypertension, arrhythmia (e.g. ischemic arrhythmia, arrhythmia due to myocardial infarction, myocardial stunning, myocardial dysfunction, arrhythmia after PTCA or after thrombolysis, etc.), angina pectoris, cardiac hypertrophy, myocardial infarction, heart failure (e.g., congestive heart failure, acute heart failure, cardiac hypertrophy, etc.), restenosis after PTCA, PTCI (percutaneous transluminal coronary intervention), and shock (e.g., hemorrhagic shock, endotoxin shock, etc.); renal diseases e.g., diabetes mellitus, diabetic nephropathy, ischemic acute renal insufficiency, etc.; organ disorders associated with ischemia or ischemic reperfusion e.g.,
  • the formulations of this invention can be used for myocardial protection before, during, or after CABG surgeries, vascular surgeries, PTCA, organ transplantation, or non-cardiac surgeries.
  • the formulations of this invention can be used for myocardial protection in patients presenting with ongoing cardiac (acute coronary syndromes, e.g., myocardial infarction or unstable angina) or cerebral ischemic events (e.g., stroke).
  • the formulations of this invention can be used for chronic myocardial protection in patients with diagnosed coronary heart disease (e.g., previous myocardial infarction or unstable angina) or patients who are at high risk for myocardial infarction (age greater than 65 and two or more risk factors for coronary heart disease).
  • diagnosed coronary heart disease e.g., previous myocardial infarction or unstable angina
  • patients who are at high risk for myocardial infarction e.g., age greater than 65 and two or more risk factors for coronary heart disease.
  • compositions of the invention are provided.
  • the invention provides an intravenous (IV) solution comprising a selected concentration of ranolazine.
  • the IV solution preferably comprises about 1.5 to about 3.0 mg of ranolazine per milliliter of a pharmaceutically acceptable aqueous solution, more preferably about 1.8 to about 2.2 mg and even more preferably about 2 mg.
  • the IV solution preferably contains no viscous components including by way of example as propylene glycol or polyethylene glycol (e.g., polyethylene glycol 400). It is understood that minor amounts of viscous components that do not materially alter the viscosity may be included in the intravenous formulations of this invention.
  • the viscosity of the IV solution is preferably less than 10 cSt (centistokes) at 20 0 C, more preferably less than 5 cSt at 20 0 C and even more preferably less than 2 cSt at 20 0 C.
  • the IV solution comprises: about 1.5 to about 3.0 mg of ranolazine per mL of IV solution; and either about 4.8 to about 5.0 weight percent dextrose or about 0.8 to about 1.0 weight percent sodium chloride.
  • the IV solution comprises: about 1.8 to about 2.2 mg of ranolazine per mL of IV solution; and either about 4.8 to about 5.0 weight percent dextrose or about 0.8 to about 1.0 weight percent sodium chloride.
  • the IV solution of this invention comprises: about 2 mg of ranolazine per mL of IV solution; and either about 4.8 to about 5.0 weight percent dextrose or about 0.9 weight percent sodium chloride.
  • the IV solutions described herein can be prepared from a stock solution comprising a 20 mL container for single use delivery which container comprises a sterile aqueous solution of ranolazine at a concentration of about 25 mg/mL; either about 36 mg/mL dextrose monohydrate or about 0.9 weight percent sodium chloride; and having a pH of about 4.
  • a stock solution comprising a 20 mL container for single use delivery which container comprises a sterile aqueous solution of ranolazine at a concentration of about 25 mg/mL; either about 36 mg/mL dextrose monohydrate or about 0.9 weight percent sodium chloride; and having a pH of about 4.
  • employing such high concentrations of ranolazine and dextrose monohydrate or ranolazine and sodium chloride in the stock solutions provide for compositions which are stable and have adequate shelf-lives, preferably of greater than 6 months.
  • containers described herein are injected into an IV container containing 460 mL of sterile saline (0.9 weight percent (w%) sodium chloride) or an aqueous dextrose solution (water containing 5 weight percent dextrose monohydrate) to provide for an IV solution of about 2 mg/mL of ranolazine maintained at physiologically acceptable pH.
  • Containers useful herein include, but are not limited to, vials, syringes, bottles, IV bags, and the like.
  • the intravenous formulation as above is diluted with a sterile diluent prior to use.
  • the sterile diluent is 5 % dextrose or a 0.9 weight percent saline solution.
  • the intravenous formulation is further diluted into bags of sterile diluent.
  • a formulation of ranolazine is an oral formulation.
  • an oral formulation of ranolazine is a tablet.
  • the tablet of ranolazine is up to 500 mg.
  • the tablet of ranolazine is up to 1000 mg.
  • the ranolazine tablet is 375 mg, and/or 500 mg.
  • ranolazine is thoroughly discussed in U.S. Patent No. 6,303,607 and U.S. Publication No. 2003/0220344, which are both incorporated herein by reference in their entirety.
  • the oral sustained release ranolazine dosage formulations of this invention are administered one, twice, or three times in a 24 hour period in order to maintain a plasma ranolazine level above the threshold therapeutic level and below the maximally tolerated levels, which is preferably a plasma level of about 550 to 7500 ng base/mL in a patient.
  • the plasma level of ranolazine ranges about 1500- 3500 ng base/mL.
  • the oral ranolazine dosage forms described herein are administered once or twice daily. If the dosage forms are administered twice daily, then it is preferred that the oral ranolazine dosage forms are administered at about twelve hour intervals.
  • sustained release dosage forms of this invention are administered in a manner that allows for a peak ranolazine level no more than 8 times greater than the trough ranolazine level, preferably no more than 4 times greater than the trough ranolazine level, preferably no more than 3 times greater than the trough ranolazine level, and most preferably no greater than 2 times trough ranolazine level.
  • the sustained release ranolazine formulations of this invention provide the therapeutic advantage of minimizing variations in ranolazine plasma concentration while permitting, at most, twice-daily administration.
  • the formulation may be administered alone, or (at least initially) in combination with an immediate release formulation if rapid achievement of a therapeutically effective plasma concentration of ranolazine is desired or by soluble IV formulations and oral dosage forms.
  • the formulations of the invention can be used for treating various diseases, such as, cardiovascular diseases e.g., arteriosclerosis, hypertension, arrhythmia (e.g. ischemic arrhythmia, arrhythmia due to myocardial infarction, myocardial stunning, myocardial dysfunction, arrhythmia after PTCA or after thrombolysis, etc.), angina pectoris, cardiac hypertrophy, myocardial infarction, heart failure (e.g., congestive heart failure, acute heart failure, cardiac hypertrophy, etc.), restenosis after PTCA, PTCI (percutaneous transluminal coronary intervention), and shock (e.g., hemorrhagic shock, endotoxin shock, etc.); renal diseases e.g., diabetes mellitus, impaired glucose tolerance or pre-diabetes, diabetic nephropathy, ischemic acute renal insufficiency, etc.; organ disorders associated with ischemia or
  • the formulations of this invention can be used for myocardial protection before, during, or after CABG surgeries, vascular surgeries, PTCA, organ transplantation, or non-cardiac surgeries.
  • the formulations of this invention can be used for myocardial protection in patients presenting with ongoing cardiac (acute coronary syndromes, e.g., myocardial infarction or unstable angina) or cerebral ischemic events (e.g., stroke).
  • the formulations of this invention can be used for chronic myocardial protection in patients with diagnosed coronary heart disease (e.g., previous myocardial infarction or unstable angina) or patients who are at high risk for myocardial infarction (age greater than 65 and two or more risk factors for coronary heart disease).
  • diagnosed coronary heart disease e.g., previous myocardial infarction or unstable angina
  • patients who are at high risk for myocardial infarction e.g., age greater than 65 and two or more risk factors for coronary heart disease.
  • the compounds of the invention are usually administered in the form of pharmaceutical compositions.
  • This invention therefore provides pharmaceutical compositions that contain, as the active ingredient, one or more of the compounds of the invention, or an isomer thereof, or a pharmaceutically acceptable salt or ester thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants.
  • the compounds of the invention may be administered alone or in combination with other therapeutic agents.
  • compositions are prepared in a manner well known in the pharmaceutical art (see, e.g., Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, PA 17 th Ed. (1985) and "Modern Pharmaceutics", Marcel Dekker, Inc. 3 rd Ed. (G.S. Banker & CT. Rhodes, Eds.).
  • compositions of the present invention are incorporated for administration by injection.
  • forms in which the novel compositions of the present invention may be incorporated for administration by injection include aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.
  • Aqueous solutions in saline are also conventionally used for injection, but less preferred in the context of the present invention.
  • Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be employed.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Sterile injectable solutions are prepared by incorporating the compound of the invention in the required amount in the appropriate solvent with various other ingredients as enumerated above, as required, followed by filtration and sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile- filtered solution thereof.
  • Oral administration is another route for administration of the compounds of Formula I. Administration may be via tablet, capsule or enteric-coated tablets, or the like.
  • the active ingredient is usually diluted by an excipient and/or enclosed within a carrier such that the formulation can be in the form of a capsule, sachet, paper or other container.
  • the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material (as above), which acts as a vehicle, carrier or medium for the active ingredient.
  • compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
  • excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose.
  • the formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
  • compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.
  • Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Patent Nos. 3,845,770; 4,326,525; 4,902,514; 5,616,345; and WO 0013687.
  • Another formulation for use in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts.
  • compositions are preferably formulated in a unit dosage form.
  • unit dosage forms refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient (e.g., a tablet, capsule, ampoule).
  • suitable pharmaceutical excipient e.g., a tablet, capsule, ampoule.
  • the compounds of Formula I are effective over a wide dosage range and are generally administered in a pharmaceutically effective amount.
  • each dosage unit contains from 10 mg to 2 g of a compound of Formula I, more preferably 10 to 1500 mg, more preferably from 10 to 1000 mg, more preferably from 10 to 700 mg, and for parenteral administration, preferably from 10 to 700 mg of a compound of Formula I, more preferably about 50 to 200 mg.
  • the amount of the compound of Formula I actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
  • the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention.
  • these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
  • the tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach.
  • the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
  • the two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
  • enteric layers or coatings such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
  • the preferred compositions of the invention are formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient, especially sustained release formulations.
  • the most preferred compound of the invention is ranolazine, which is named ( ⁇ )-N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2 methoxyphenoxy) propyl] -1-piperazine-acetamide, or its isomers, or its pharmaceutically effective salts.
  • ranolazine plasma concentrations used in the specification and examples refer to ranolazine free base.
  • the preferred sustained release formulations of this invention are preferably in the form of a compressed tablet comprising an intimate mixture of compound and a partially neutralized pH-dependent binder that controls the rate of dissolution in aqueous media across the range of pH in the stomach (typically approximately 2) and in the intestine (typically approximately about 5.5).
  • An example of a sustained release formulation is disclosed in U.S. Patents 6,303,607; 6,479,496; 6,369,062; and 6,525,057, the complete disclosures of which are hereby incorporated by reference.
  • one or more pH-dependent binders are chosen to control the dissolution profile of the compound so that the formulation releases the drug slowly and continuously as the formulation passed through the stomach and gastrointestinal tract.
  • the dissolution control capacity of the pH-dependent binder(s) is particularly important in a sustained release formulation because a sustained release formulation that contains sufficient compound for twice daily administration may cause untoward side effects if the compound is released too rapidly ("dose-dumping").
  • the pH-dependent binders suitable for use in this invention are those which inhibit rapid release of drug from a tablet during its residence in the stomach (where the pH is below about 4.5), and which promotes the release of a therapeutic amount of compound from the dosage form in the lower gastrointestinal tract (where the pH is generally greater than about 4.5).
  • enteric binders and coating agents have the desired pH dissolution properties.
  • phthalic acid derivatives such as the phthalic acid derivatives of vinyl polymers and copolymers, hydroxyalkylcelluloses, alkylcelluloses, cellulose acetates, hydroxyalkylcellulose acetates, cellulose ethers, alkylcellulose acetates, and the partial esters thereof, and polymers and copolymers of lower alkyl acrylic acids and lower alkyl acrylates, and the partial esters thereof.
  • Preferred pH-dependent binder materials that can be used in conjunction with the compound to create a sustained release formulation are methacrylic acid copolymers.
  • Methacrylic acid copolymers are copolymers of methacrylic acid with neutral acrylate or methacrylate esters such as ethyl acrylate or methyl methacrylate.
  • a most preferred copolymer is methacrylic acid copolymer, Type C, USP (which is a copolymer of methacrylic acid and ethyl acrylate having between 46.0% and 50.6% methacrylic acid units).
  • Such a copolymer is commercially available, from R ⁇ hm Pharma as Eudragit® L 100-55 (as a powder) or L30D-55 (as a 30% dispersion in water).
  • pH-dependent binder materials which may be used alone or in combination in a sustained release formulation dosage form include hydroxypropyl cellulose phthalate, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, polyvinylacetate phthalate, polyvinylpyrrolidone phthalate, and the like.
  • One or more pH-independent binders may be in used in sustained release formulations in oral dosage forms.
  • pH-dependent binders and viscosity enhancing agents such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, polyvinylpyrrolidone, neutral poly(meth)acrylate esters, and the like, may not themselves provide the required dissolution control provided by the identified pH-dependent binders.
  • the pH-independent binders may be present in the formulation of this invention in an amount ranging from about 1 to about 10 wt%, and preferably in amount ranging from about 1 to about 3 wt% and most preferably about 2.0 wt%.
  • ranolazine As shown in Table 1, the preferred compound of the invention, ranolazine, is relatively insoluble in aqueous solutions having a pH above about 6.5, while the solubility begins to increase dramatically below about pH 6.
  • Increasing the pH-dependent binder content in the formulation decreases the release rate of the sustained release form of the compound from the formulation at pH is below 4.5 typical of the pH found in the stomach.
  • the enteric coating formed by the binder is less soluble and increases the relative release rate above pH 4.5, where the solubility of compound is lower.
  • a proper selection of the pH-dependent binder allows for a quicker release rate of the compound from the formulation above pH 4.5, while greatly affecting the release rate at low pH.
  • Partial neutralization of the binder facilitates the conversion of the binder into a latex like film which forms around the individual granules. Accordingly, the type and the quantity of the pH-dependent binder and amount of the partial neutralization composition are chosen to closely control the rate of dissolution of compound from the formulation.
  • the dosage forms of this invention should have a quantity of pH-dependent binders sufficient to produce a sustained release formulation from which the release rate of the compound is controlled such that at low pHs (below about 4.5) the rate of dissolution is significantly slowed.
  • a suitable quantity of pH-dependent binder is between 5% and 15%.
  • the pH dependent binder will typically have from about 1 to about 20 % of the binder methacrylic acid carboxyl groups neutralized. However, it is preferred that the degree of neutralization ranges from about 3 to 6%.
  • the sustained release formulation may also contain pharmaceutical excipients intimately admixed with the compound and the pH-dependent binder.
  • Pharmaceutically acceptable excipients may include, for example, pH-independent binders or film- forming agents such as hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, polyvinylpyrrolidone, neutral poly(meth)acrylate esters (e.g. the methyl methacrylate/ethyl acrylate copolymers sold under the trademark Eudragit® NE by R ⁇ hm Pharma, starch,gelatin, sugars carboxymethylcellulose, and the like.
  • diluents such as lactose, mannitol, dry starch, microcrystalline cellulose and the like; surface active agents such as polyoxyethylene sorbitan esters, sorbitan esters and the like; and coloring agents and flavoring agents.
  • Lubricants such as tale and magnesium stearate
  • other tableting aids are also optionally present.
  • the sustained release formulations of this invention have an active compound content of above about 50% by weight to about 95% or more by weight, more preferably between about 70% to about 90% by weight and most preferably from about 70 to about 80% by weight; a pH-dependent binder content of between 5% and 40%, preferably between 5% and 25%, and more preferably between 5% and 15%; with the remainder of the dosage form comprising pH-independent binders, fillers, and other optional excipients.
  • Active ingredient 50-95 70-90 75 Microcrystalline cellulose (filler) 1-35 5-15 10.6 Methacrylic acid copolymer 1-35 5-12.5 10.0 Sodium hydroxide 0.1-1.0 0.2-0.6 0.4 Hydroxypropyl methylcellulose 0.5-5.0 1-3 2.0 Magnesium stearate 0.5-5.0 1-3 2.0
  • the sustained release formulations of this invention are prepared as follows: compound and pH-dependent binder and any optional excipients are intimately mixed(dry-blended). The dry-blended mixture is then granulated in the presence of an aqueous solution of a strong base that is sprayed into the blended powder. The granulate is dried, screened, mixed with optional lubricants (such as talc or magnesium stearate), and compressed into tablets.
  • Preferred aqueous solutions of strong bases are solutions of alkali metal hydroxides, such as sodium or potassium hydroxide, preferably sodium hydroxide, in water (optionally containing up to 25% of water-miscible solvents such as lower alcohols).
  • the resulting tablets may be coated with an optional film- forming agent, for identification, taste-masking purposes and to improve ease of swallowing.
  • the film forming agent will typically be present in an amount ranging from between 2% and 4% of the tablet weight.
  • Suitable film-forming agents are well known to the art and include hydroxypropyl. methylcellulose, cationic methacrylate copolymers (dimethylaminoethyl methacrylate/ methyl-butyl methacrylate copolymers - Eudragit® E - R ⁇ hm. Pharma), and the like.
  • These film- forming agents may optionally contain colorants, plasticizers, and other supplemental ingredients.
  • the compressed tablets preferably have a hardness sufficient to withstand 8 Kp compression.
  • the tablet size will depend primarily upon the amount of compound in the tablet.
  • the tablets will include from 300 to 1100 mg of compound free base.
  • the tablets will include amounts of compound free base ranging from 400-600 mg, 650-850 mg, and 900-1100 mg.
  • the time during which the compound containing powder is wet mixed is controlled.
  • the total powder mix time i.e. the time during which the powder is exposed to sodium hydroxide solution, will range from 1 to 10 minutes and preferably from 2 to 5 minutes.
  • the particles are removed from the granulator and placed in a fluid bed dryer for drying at about 60 0 C.
  • the method is effective in the treatment of diabetes.
  • Examples 1-4 illustrate the preparation of representative pharmaceutical formulations containing a compound of Formula I.
  • compositions are Compositions:
  • Stopper Rubber, 20-mm, West 4432/50, gray butyl, teflon coated
  • ranolazine is manufactured via an aseptic fill process as follows.
  • WFI Water for Injection
  • the required amount of ranolazine was added to the dextrose solution.
  • the solution pH was adjusted to a target of 3.88-3.92 with an 0.1 N or 1.0 N HCl solution. Additionally, 1 N NaOH may have been utilized to further adjust the solution to the target pH of 3.88-3.92.
  • the batch was adjusted to the final weight with WFI.
  • ranolazine-formulated bulk solution was sterilized by sterile filtration through two 0.2 ⁇ m sterile filters. Subsequently, the sterile ranolazine-formulated bulk solution was aseptically filled into sterile glass vials and aseptically stoppered with sterile stoppers. The stoppered vials were then sealed with clean flip-top aluminum overseals. The vials then went through a final inspection.
  • Stopper Rubber, 20-mm, West 4432/50, gray butyl
  • WFI Water for Injection
  • a suitable vessel at about 90% of the final batch weight.
  • About 90-95% of the required amount of 5 N HCl is added into the compounding vessel.
  • the required amount of ranolazine is slowly added, followed by the addition of dextrose monohydrate into the ranolazine solution.
  • the solution pH is adjusted with 5 N HCl solution to a target of 3.9-4.1.
  • the batch is subsequently adjusted to the final weight with WFI.
  • the ranolazine- formulated bulk solution is sterilized by filtration through two redundant 0.22 ⁇ m sterilizing filters.
  • the sterile ranolazine-formulated bulk solution is then aseptically filled into 20 mL sterile/depyrogenated vials and aseptically stoppered with sterile/depyrogenated stoppers.
  • the stoppered vials are sealed with clean flip-top aluminum overseals.
  • the sealed vials are terminally sterilized by a validated terminal sterilization cycle at 121.1 0 C for 30 minutes. After the terminal sterilization process, the vials go through an inspection. To protect the drug product from light, the vials are individually packaged into carton boxes.
  • NSTEACS non-ST- Elevation Acute Coronary Syndrome
  • NSTEACS non-ST elevation acute coronary syndrome
  • MERLIN-TIMI 36 randomized 6560 patients at presentation with NSTEACS were treated with either placebo or the anti-ischemic agent ranolazine, which has also been associated with improved glycemic parameters. Median clinical follow-up was 12 months.
  • Metabolic syndrome was defined as having any 3 of the following: 1) waist circumference >102cm (men) and >88cm (women), 2) triglycerides (TG) >150 mg/dL or drug treatment for elevated TG, 3) High density lipoproteins (HDL) ⁇ 40 mg/dL (men) and ⁇ 50 mg/dL (women), or drug treatment for reduced HDL, 4) Systolic blood pressure (SBP) >130 mmHg or diastolic blood pressure (DBP) >85 mmHg or drug treatment for hypertension, and 5) fasting glucose >100 mg/dL.
  • SBP Systolic blood pressure
  • DBP diastolic blood pressure
  • Metabolic syndrome and diabetes are common among patients presenting with NSTEACS and confer increased cardiovascular risk.
  • Compound and pH-dependent binder and any optional excipients are intimately mixed (dry-blended).
  • the dry-blended mixture is then granulated in the presence of an aqueous solution of a strong base that is sprayed into the blended powder.
  • the granulate is dried, screened, mixed with optional lubricants (such as talc or magnesium stearate), and compressed into tablets.
  • Preferred aqueous solutions of strong bases are solutions of alkali metal hydroxides, such as sodium or potassium hydroxide, preferably sodium hydroxide, in water (optionally containing up to 25% of water-miscible solvents such as lower alcohols).
  • the resulting tablets may be coated with an optional film- forming agent, for identification, taste- masking purposes and to improve ease of swallowing.
  • the film forming agent will typically be present in an amount ranging from between 2% and 4% of the tablet weight.
  • Suitable film-forming agents are well known to the art and include hydroxypropyl. methylcellulose, cationic methacrylate copolymers (dimethylaminoethyl methacrylate/ methyl-butyl methacrylate copolymers - Eudragit® E - R ⁇ hm. Pharma), and the like.
  • These film- forming agents may optionally contain colorants, plasticizers, and other supplemental ingredients.
  • the compressed tablets preferably have a hardness sufficient to withstand 8 Kp compression.
  • the tablet size will depend primarily upon the amount of compound in the tablet.
  • the tablets will include from 300 to 1100 mg of compound free base.
  • the tablets will include amounts of compound free base ranging from 400-600 mg, 650-850 mg, and 900-1100 mg.
  • the time during which the compound containing powder is wet mixed is controlled.
  • the total powder mix time i.e. the time during which the powder is exposed to sodium hydroxide solution, will range from 1 to 10 minutes and preferably from 2 to 5 minutes.
  • the particles are removed from the granulator and placed in a fluid bed dryer for drying at about 60 0 C.
  • HbAIc levels were assayed following a modification of the method of Phillipov (Components of total measurement error for hemoglobin AIc determination. Phillipov, G., et al. Clin. Chem. (2001), 47(10): 1851). (see Figure 2)
  • Test compounds dissolved in DMSO and suspended in 0.5% tylose, are administered perorally by means of a pharyngeal tube to Syrian gold hamsters.
  • blood samples approximately 25O.mu.l
  • the compounds are subsequently administered perorally using a pharyngeal tube.
  • Identical volumes of solvent without compounds are administered to the control animals.
  • the animals are fasted.
  • blood samples are taken by puncture of the retro-orbital venous plexus.
  • the blood samples are coagulated by incubation at 4°C. overnight.
  • the samples are centrifuged at 6000 X.g for 10 minutes.
  • concentration of cholesterol and triglycerides in the resulting serum are determined using modifications of commercially available enzyme tests (cholesterol enzymatic 14366 Merck, triglycerides 14364 Merck).
  • insulin-dependent diabetes mellitus can be induced by chemical destruction of the pancreas with an i.v. injection of STZ (60 mg/kg, controls can be given saline vehicle).
  • the volume of the injection is equivalent to 0.1 ml/100 g body weight.
  • the injection is delivered into the pre-cannulated jugular vein of young (190-220 g) male Sprague Dawley rats (see below for procedure).
  • osmotic mini pumps are implanted subcutaneously (see below for procedure) to deliver drugs at a constant rate over the course of the study.
  • a second mini pump may need to be implanted.
  • animals In order to confirm the diabetic state, animals have a blood sample taken from the tail (snip the end off the tail) and their blood glucose determined. Animals with blood glucose levels exceeding 13 mM are considered diabetic and randomized into 4 groups. Two groups receive insulin injections subcutaneously daily to achieve partial glucose control (fasting glucose levels approximately 50% of uncontrolled diabetic animals). One of the partially controlled diabetic groups is treated with the test compound. In addition, two non-diabetic groups are included, one receives the test compound and one does not. Neither of the non-diabetic groups of rats receive insulin.
  • a small area of the neck is shaved and cleaned extensively with an iodine solution, a small 1-cm incision using a scalpel is made in the dermal layer and the pump is inserted aseptically port-first into the Sub-Q space. The incision is then closed with 1-2 surgical staples as required.
  • Implantation of carotid artery catheter for measurement of blood pressure and implementation of oral glucose tolerance test is provided.
  • an anesthetized rat is laid on its back with the head toward the surgeon and lubricating ointment placed in both eyes.
  • a midline incision is made along the neck to expose the left common carotid artery.
  • a tunnel is made for the catheter using blunt dissection in the subcutaneous pocket on the dorsal section of the neck where it is externalized.
  • Half- curved forceps are used to isolate the artery and soft plastic tubing passed under the posterior portion of the artery to temporarily impede the blood flow to the isolated area.
  • the anterior portion of the external carotid artery is then ligated with a piece of 4-0 silk suture and light tension is created on the artery by anchoring a pair of hemostats to the ends of the suture material.
  • the external carotid is then semi-transected and a 0.033 or 0.040 mm O.D. catheter inserted and pushed toward the aorta, (around 2-3- cm deep).
  • the catheter is tied in place, secured to the pectoral muscle to prevent removal of the catheter, and the anterior portion of the external carotid permanently ligated and observed for any leakage of blood.
  • the catheter is tied at the back of the neck and a piece of suture tied around the knot leaving both ends about 2 inches long for retrieval from under the skin.
  • the knotted catheter is retracted back under the skin to prevent being pulled out by the rat.
  • the catheter is attached to a pressure transducer and a data-acquisition system.
  • the catheter is attached to a needle and syringe for collection of blood samples.
  • insulin-dependent diabetes mellitus are induced by chemical destruction of the pancreas with an i.v. injection of STZ (60 mg/kg, controls are given saline vehicle).
  • the volume of the injection is equivalent to 0.1 ml/100 g body weight.
  • the injection is delivered into the pre-cannulated jugular vein of young (280-300 g) male Sprague Dawley rats with 2 catheters surgically implanted in the jugular vein and external carotid artery.
  • animals have a blood sample taken from the cannula and their blood glucose is determined. Animals with blood glucose levels exceeding 13 mM are considered diabetic.
  • the pre-implanted catheter is flushed daily with heparinized saline to maintain patency.
  • rats undergo pharmacokinetic studies with the compounds of the invention. Animals have their catheters retrieved from under the skin and tested for patency.
  • An injection plug is attached to a 19-gauge IV set, filled with 0.1% heparinized saline and the needle end inserted into the catheters.
  • the test compound(s) is (are) administered via the jugular vein catheter either by bolus injection or steady infusion, or by oral gavage (1 ml/kg and 2ml/kg, respectively).
  • 300 ⁇ l of blood is drawn from the line in the carotid artery and 300 ⁇ l saline flushed in to replace blood volume.
  • 300 ⁇ l of blood at 10 time points from a 300 gm animal represents ⁇ 10% total blood volume. If a 24-hour sample is drawn, the catheters are tied off at skin level and the animals returned to their cages. They are then sacrificed at 24 hours by exanguination under anesthesia to collect the last blood sample. If there is no 24- hour sample, the animals are sacrificed by exanguination under anesthesia at the last blood collection.
  • the CARISA Combination Assessment of Ranolazine in Stable Angina
  • study randomized 823 symptomatic chronic angina patients on diltiazem, atenolol or amlodipine to ranolazine 750 mg bid, 1000 mg bid or placebo in a parallel, double- blind, 12 week study.
  • Modified Bruce treadmill tests were performed at baseline, and after 2, 6, and 12 weeks of treatment at trough and peak plasma levels.
  • the ranolazine formulation used in this study was that shown in Example 4.
  • the ranolazine formulation used in the CARISA and MARISA studies was that shown in Example 4. The most frequently reported adverse events (dizziness constipation and nausea) were generally mild and occurred in fewer than 10% of patients. The potential use of ranolazine in diabetics is of interest because approximately one in four angina patients has diabetes.
  • MERLIN-TIMI 36 randomized patients with non-ST elevation ACS to ranolazine or placebo to compare HbAIc (%) and the time to onset of worsening hyperglycemia (>1% increase in HbAIc).
  • HbAIc data are reported as least-square means. Patients categorized as "diabetic” had been diagnosed as diabetic before or at the time of randomization. Patients categorized as "no diabetes” had not been diagnosed as diabetic before or at the time of randomization. Some patients characterized as "no diabetes” may have been diagnosed as "diabetic" during the trial; however, these patients are still listed in the "no diabetes” category in Figure 8B. Results

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
EP07797962A 2007-05-31 2007-05-31 Method of treating diabetes Withdrawn EP2152268A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2007/070140 WO2008147417A1 (en) 2007-05-31 2007-05-31 Method of treating diabetes

Publications (1)

Publication Number Publication Date
EP2152268A1 true EP2152268A1 (en) 2010-02-17

Family

ID=38812044

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07797962A Withdrawn EP2152268A1 (en) 2007-05-31 2007-05-31 Method of treating diabetes

Country Status (11)

Country Link
EP (1) EP2152268A1 (ko)
JP (1) JP2010528112A (ko)
KR (1) KR20100038322A (ko)
CN (1) CN101678017A (ko)
AU (1) AU2007354300A1 (ko)
BR (1) BRPI0721741A2 (ko)
CA (1) CA2687381A1 (ko)
IL (1) IL202002A0 (ko)
MX (1) MX2009012957A (ko)
NO (1) NO20093592L (ko)
WO (1) WO2008147417A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822473B2 (en) 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
US20040063717A1 (en) 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
RU2691620C1 (ru) * 2018-11-26 2019-06-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Астраханский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО Астраханский ГМУ Минздрава России) Способ прогнозирования риска развития ишемической болезни сердца у пациентов с сахарным диабетом 2 типа в сочетании с субклиническим тиреотоксикозом
CN110812344A (zh) * 2019-12-17 2020-02-21 卓和药业集团有限公司 一种治疗糖尿病合并心绞痛的药物组合物及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US20040063717A1 (en) * 2002-05-21 2004-04-01 Andrew Wolff Method of treating diabetes
BRPI0606403A2 (pt) * 2005-01-06 2009-06-23 Cv Therapeutics Inc formulações farmacêuticas com liberação sustentada e seus usos

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008147417A1 *

Also Published As

Publication number Publication date
IL202002A0 (en) 2010-06-16
BRPI0721741A2 (pt) 2013-02-13
MX2009012957A (es) 2010-03-03
KR20100038322A (ko) 2010-04-14
WO2008147417A1 (en) 2008-12-04
JP2010528112A (ja) 2010-08-19
NO20093592L (no) 2010-01-20
CA2687381A1 (en) 2008-12-04
AU2007354300A1 (en) 2008-12-04
CN101678017A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
US8883750B2 (en) Method of treating diabetes
US6528511B2 (en) Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
US8822473B2 (en) Method of treating diabetes
US20080193530A1 (en) Use of ranolazine for the treatment of non-coronary microvascular diseases
WO2008147417A1 (en) Method of treating diabetes
CN111329841B (zh) 格列齐特缓释片及其制备方法
JP2011511844A (ja) 心血管疾患の処置のためのラノラジンの使用
RU2442585C2 (ru) Способ лечения диабета
CN101658673A (zh) 治疗糖尿病的方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20091125

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: JERLING, MARCUS

Inventor name: WOLFF, ANDREW

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1141223

Country of ref document: HK

17Q First examination report despatched

Effective date: 20120427

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GILEAD SCIENCES, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120908

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1141223

Country of ref document: HK